Case Study:

Speed up regulatory processes with AI

How AI is helping regulatory teams increase productivity and dossier updates

The traditional approach to regulatory dossier review—manually comparing hundreds of pages against multiple regulatory guidances—represents a critical pain point for pharmaceutical companies seeking to accelerate drug approvals. This case study showcases how one company leveraged AI technology to transform this labor-intensive process into a streamlined, automated workflow.

The Client

A pharmaceutical company was facing significant operational inefficiencies in their regulatory affairs department. The team was spending excessive amounts of time manually comparing drug dossiers against various regulatory guidances from agencies like the FDA, EMA, and other global regulatory bodies. This process involved:

  • Line-by-line review of hundreds of pages of technical documentation
  • Cross-referencing multiple, frequently updated regulatory guidelines
  • Identifying discrepancies and required modifications across different sections
  • Determining the scope and priority of necessary changes
  • Coordinating revisions across multiple therapeutic areas and submission types

The manual nature of this work created bottlenecks in the regulatory submission process, delayed time-to-market for critical medications, and consumed valuable resources that could have been allocated to more strategic regulatory activities.

The Solution

The company developed a sophisticated AI-powered regulatory intelligence system designed to automate and enhance the dossier review process. The solution incorporated:

  • Natural language processing algorithms trained on regulatory guidances and submission requirements
  • Machine learning models capable of understanding pharmaceutical terminology and regulatory language nuances
  • Automated comparison engines that could identify content gaps, inconsistencies, and non-compliance issues
  • A classification system that categorized required changes by severity level (minor, moderate, major) based on regulatory impact and submission risk
  • Intelligent recommendation engines that provided specific, actionable guidance for addressing identified issues
  • Integration with existing document management systems to streamline workflow

 

The AI system was trained on historical successful submissions, regulatory feedback, and guidance documents to ensure accuracy and relevance of its recommendations.

The Outcome

The implementation delivered transformative results for the regulatory affairs team:

  • 81% reduction in regulatory work process time, dramatically accelerating submission timelines
  • Significant improvement in submission quality and regulatory compliance rates
  • Enhanced ability to identify critical issues early in the review process
  • Reduced regulatory review cycles and faster approval timelines
  • Freed up senior regulatory professionals to focus on strategic planning, agency interactions, and complex regulatory problem-solving
  • Improved consistency across different therapeutic areas and submission types
  • Better risk management through more thorough and systematic review processes

 

This efficiency gain translated into faster patient access to new treatments and substantial cost savings for the organization while maintaining the highest standards of regulatory compliance.

To achieve these kinds of results, contact Eularis today.

Discover how AI can deliver growth for you.

Get Started Today!

Become A Member

Latest News

Read our latest blogs here.